 Ocuphire Pharma Inc NASDAQ: OCUP announced data from the VEGA-1 Phase 2 trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine LDP in presbyopic subjects. Presbyopic is the gradual loss of the eyes ability to focus on nearby objects. 